{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06299410",
            "orgStudyIdInfo": {
                "id": "ITI-1284-008"
            },
            "organization": {
                "fullName": "Intra-Cellular Therapies, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects",
            "officialTitle": "An Open-label, Positron Emission Tomography Study to Evaluate Brain Receptor Occupancy, Safety, Tolerability, and Pharmacokinetics After a Single Sublingual Administration of ITI-1284 in Healthy Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "pet-study-to-evaluate-brain-receptor-occupancy-safety-and-pharmacokinetics-of-iti-in-healthy-subjects"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-01",
            "studyFirstSubmitQcDate": "2024-03-01",
            "studyFirstPostDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Intra-Cellular Therapies, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor in healthy subjects. Subjects will enroll in one of the 2 cohorts, will have a baseline PET/CT scan, will receive a single dose of ITI-1284, and undergo one postdose PET/CT scan."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort A1: 10 mg ITI-1284",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-1284 10 mg"
                    ]
                },
                {
                    "label": "Cohort A2: 20 mg ITI-1284",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-1284 20 mg"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ITI-1284 10 mg",
                    "description": "ITI-1284 tablet",
                    "armGroupLabels": [
                        "Cohort A1: 10 mg ITI-1284"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "ITI-1284 20 mg",
                    "description": "ITI-1284 tablet",
                    "armGroupLabels": [
                        "Cohort A2: 20 mg ITI-1284"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "% Receptor occupancy",
                    "description": "Percent change of binding potential from baseline",
                    "timeFrame": "Day 1"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics: AUC0-t",
                    "description": "Area under the plasma drug concentration-time curve (AUC) from time zero to the last measurable concentration",
                    "timeFrame": "Predose and multiple timepoints up to 24 hours postdose on Day 1"
                },
                {
                    "measure": "Pharmacokinetics: Cmax",
                    "description": "Maximum plasma concentration",
                    "timeFrame": "Predose and multiple timepoints up to 24 hours postdose on Day 1"
                },
                {
                    "measure": "Pharmacokinetics: Tmax",
                    "description": "Time of maximum plasma concentration",
                    "timeFrame": "Predose and multiple timepoints up to 24 hours postdose on Day 1"
                },
                {
                    "measure": "Percentage of subjects with treatment-emergent adverse events",
                    "timeFrame": "Up to 30 days after the dose of study drug"
                },
                {
                    "measure": "Change from baseline in ECG QT interval",
                    "timeFrame": "Up to Day 3"
                },
                {
                    "measure": "Change from baseline in aspartate aminotransferase",
                    "timeFrame": "Up to Day 3"
                },
                {
                    "measure": "Change from baseline in alanine aminotransferase",
                    "timeFrame": "Up to Day 3"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and female subjects between 18 and 50 years old (inclusive);\n* BMI inclusive of 18-32 kg/m2 at screening and a minimum weight of 50 kg;\n* Willingness to remain in the hospital research unit for the duration of the inpatient period.\n\nExclusion Criteria:\n\n* Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the subject at risk or interfere with study outcome variables; this includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, gastrointestinal, pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy;\n* Clinically significant abnormal findings in vital sign assessments, supine SBP \\> 140 mmHg or \\< 90 mmHg, or supine DBP \\>90 mmHg or \\< 50 mmHg or pulse rate \\> 100 bpm or \\< 45 bpm at Screening;\n* History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study;\n* Any condition which would preclude MRI or PET/CT examination (eg, implanted metal, claustrophobia, unable to fit in PET/CT or MRI scanners);\n* Contraindications based on any previous MRI or the study MRI performed prior to the baseline PET/CT scan.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ITI Clinical Trials",
                    "role": "CONTACT",
                    "phone": "646 440-9333",
                    "email": "ITCIClinicalTrials@itci-inc.com"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Site 1",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06520",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}